Xingjuan Chao Sells 20,846 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 20,846 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $25.03, for a total value of $521,775.38. Following the transaction, the chief executive officer owned 746,345 shares in the company, valued at $18,681,015.35. This trade represents a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Xingjuan Chao also recently made the following trade(s):

• On Wednesday, September 2nd, Xingjuan Chao sold 39,540 shares of CeriBell stock. The stock was sold at an average price of $24.61, for a total value of $973,079.40.
• On Friday, August 21st, Xingjuan Chao sold 6,068 shares of CeriBell stock. The shares were sold at an average price of $24.02, for a total value of $145,753.36.
• On Wednesday, August 19th, Xingjuan Chao sold 31,415 shares of CeriBell stock. The stock was sold at an average price of $25.03, for a total transaction of $786,317.45.
• On Tuesday, August 18th, Xingjuan Chao sold 2,199 shares of CeriBell stock. The stock was sold at an average price of $25.00, for a total transaction of $54,975.00.
• On Tuesday, July 7th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $19.90, for a total transaction of $776,100.00.

CeriBell Stock Performance

Shares of CBLL stock opened at $24.37 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18. The firm has a market capitalization of $935.32 million, a price-to-earnings ratio of -13.85 and a beta of 0.95. CeriBell, Inc. has a one year low of $10.85 and a one year high of $25.63. The company has a 50 day moving average price of $21.61 and a 200 day moving average price of $19.82.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The company had revenue of $28.10 million during the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. Sell-side analysts anticipate that CeriBell, Inc. will post -1.96 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Sei Investments Co. boosted its position in shares of CeriBell by 2.3% in the first quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock worth $923,000 after buying an additional 1,125 shares during the period. Strs Ohio acquired a new position in CeriBell during the 1st quarter worth approximately $27,000. Larson Financial Group LLC lifted its position in CeriBell by 1,403.1% during the 4th quarter. Larson Financial Group LLC now owns 2,871 shares of the company’s stock worth $63,000 after acquiring an additional 2,680 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in CeriBell by 8,735.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,739 shares of the company’s stock worth $60,000 after acquiring an additional 2,708 shares during the period. Finally, Legal & General Group Plc acquired a new stake in CeriBell in the second quarter valued at approximately $53,000.

Wall Street Analyst Weigh In

Several equities research analysts have commented on CBLL shares. BTIG Research restated a “buy” rating and set a $30.00 price target on shares of CeriBell in a research note on Friday, September 11th. Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. Barclays raised shares of CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. Raymond James Financial restated a “strong-buy” rating and issued a $29.00 price target on shares of CeriBell in a report on Thursday, September 3rd. Finally, Canaccord Genuity Group lifted their price target on shares of CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $24.40.

CeriBell Company Profile

Ceribell, Inc (NASDAQ: CBLL) is a medical technology company focused on improving the detection and management of seizures and other neurological conditions in hospital settings. Its products are designed to make electroencephalography (EEG) more accessible at the point of care, particularly in emergency departments, intensive care units and other settings where conventional EEG testing may be delayed or difficult to obtain.

The company’s primary offering is the Ceribell Rapid Response EEG system, which combines a portable EEG recorder, a simplified electrode headband and software for acquiring and reviewing brain-wave data.